Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Publication Date Apr 2012
Publisher GlobalData
Product Type Report
Pages 73
Single User License $ 3995.00
Site User License $ 7990.00
Corporate User License $ 11985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Leiomyosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Leiomyosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Leiomyosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Leiomyosarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Leiomyosarcoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Leiomyosarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Leiomyosarcoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Leiomyosarcoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Leiomyosarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Leiomyosarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Leiomyosarcoma Therapeutics market landscape? – Identify, understand and capitalize.


Companies Mentioned

Ariad Pharmaceuticals Merck & Co. Inc. Johnson & Johnson Pharmaceutical Research & Development, L.L.C PharmaMar S.A. Threshold Pharmaceuticals GlaxoSmithKline Eisai Co., Ltd.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Leiomyosarcoma Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Risk Factors 8
2.4 Symptoms 9
2.5 Diagnosis 9
2.5.1 Imaging of the affected area and likely areas to be affected 9
2.5.2 Procedures 10
2.5.3 Laboratory studies 10
2.6 Staging of Leiomyosarcoma 11
2.7 Treatment 12
2.7.1 Surgery 12
2.7.2 Radiation Therapy 12
2.7.3 Chemotherapy 13
2.8 GlobalData Pipeline Report Guidance 14
3 Leiomyosarcoma Therapeutics - Market Characterization 15
3.1 Leiomyosarcoma Therapeutics Major Markets, Market Size (2006-2011) - Global 15
3.2 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Global 17
3.3 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The US 19
3.4 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The US 20
3.5 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The UK 21
3.6 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The UK 22
3.7 Leiomyosarcoma Therapeutics Market Size (2006-2011) - France 23
3.8 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - France 24
3.9 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Germany 25
3.10 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Germany 26
3.11 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Italy 27
3.12 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Italy 28
3.13 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Spain 29
3.14 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Spain 30
3.15 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Japan 31
3.16 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Japan 32
3.17 Drivers and Barriers for the Leiomyosarcoma Therapeutics Market 33
3.17.1 Drivers for the Leiomyosarcoma Therapeutics Market 33
3.17.2 Barriers for the Leiomyosarcoma Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 35
4 Leiomyosarcoma Therapeutics - Competitor Assessment 36
4.1 Overview 36
4.1.1 Strategic Competitor Assessment 36
4.2 Key Takeaway 37
5 Leiomyosarcoma Therapeutics - Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.2.1 Leiomyosarcoma Therapeutics - Pre-registration Pipeline 39
5.2.2 Leiomyosarcoma Therapeutics - Phase III Pipeline 39
5.2.3 Leiomyosarcoma Therapeutics - Phase II Pipeline 40
5.2.4 Leiomyosarcoma Therapeutics - Phase I Pipeline 40
5.3 Leiomyosarcoma Therapeutics - Clinical Pipeline by Mechanism of Action 41
5.3.1 Leiomyosarcoma Therapeutics - Other Mechanisms of Action 41
5.4 Leiomyosarcoma Technology Trends Analytical Framework 42
5.5 Leiomyosarcoma Therapeutics - Promising Drugs under Clinical Development 43
5.6 Profiles of Key Late Stage Drugs under Clinical Development 44
5.6.1 Ridaforolimus 44
5.6.2 TH-302 46
5.6.3 Votrient (pazopanib) 47
5.6.4 Yondelis (trabectedin) 48
5.6.5 Halaven (eribulin mesylate) 49
5.7 Key takeaway 49
6 Leiomyosarcoma Therapeutics - Clinical Trials Mapping 50
6.1 Clinical Trials by Phase 51
6.2 Clinical Trials by Trial Status 52
6.3 Clinical Trials by Overall Sponsors 53
6.4 Clinical Trials by Prominent Sponsors 54
6.5 Top Companies Participating in Therapeutics Clinical Trials 55
7 Leiomyosarcoma Therapeutics - Strategic Assessment 56
7.1 Implications for Future Market Competition 56
8 Leiomyosarcoma Therapeutics - Future Players 57
8.1 Introduction 57
8.2 Company Profiles 57
8.2.1 Ariad Pharmaceuticals 57
8.2.2 Merck & Co. Inc. 59
8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C 60
8.2.4 PharmaMar S.A. 61
8.2.5 Threshold Pharmaceuticals 62
8.2.6 GlaxoSmithKline 62
8.2.7 Eisai Co., Ltd. 64
8.3 Other Companies in the Leiomyosarcoma Market, 2011 66
8.3.1 Leiomyosarcoma Therapeutics - Other Future Players 66
9 Leiomyosarcoma Therapeutics - Appendix 67
9.1 Market Definitions 67
9.2 Abbreviations 67
9.3 Methodology 68
9.3.1 Coverage 68
9.3.2 Secondary Research 69
9.3.3 Forecasting 69
9.3.4 Primary Research 71
9.3.5 Expert Panel Validation 72
9.4 Contact Us 72
9.5 Disclaimer 72
9.6 Bibliography 72

List of Tables
1.1 List of Tables
Table 1: Types of Leiomyosarcomas 7
Table 2: American Joint Committee on Cancer (AJCC) Staging System 11
Table 3: Musculoskeletal Tumor Society (MSTS) Staging System 11
Table 4: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 15
Table 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019 17
Table 6: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011 19
Table 7: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019 20
Table 8: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011 21
Table 9: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 22
Table 10: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 23
Table 11: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019 24
Table 12: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 25
Table 13: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 26
Table 14: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 27
Table 15: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 28
Table 16: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 29
Table 17: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 30
Table 18: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
Table 19: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 32
Table 20: Leiomyosarcoma Therapeutics - Pre-registration Pipeline, 2011 39
Table 21: Leiomyosarcoma Therapeutics - Phase III Pipeline, 2011 39
Table 22: Leiomyosarcoma Therapeutics - Phase II Pipeline, 2011 40
Table 23: Leiomyosarcoma Therapeutics - Phase I, 2011 40
Table 24: Leiomyosarcoma Therapeutics, Other Mechanisms of Action from Figure 41
Table 25: Leiomyosarcoma Therapeutics - Promising Drugs Under Clinical Development, 2011 43
Table 26: Patient Characteristics in SUCCEED Trial 44
Table 27: PFS Observed in SUCCEED Trial 45
Table 28: Adverse Events Observed During SUCCEED Trial 45
Table 29: Adverse Events Observed with the Class of mTOR Inhibitors 45
Table 30: Responses Shown by Soft Tissue Sarcoma Group in TH-302 Phase II Study 46
Table 31: Adverse Events of TH-302 47
Table 32: Hematologic Toxicity Shown by TH-302 47
Table 33: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011 50
Table 34: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Phase, 2011 51
Table 35: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Status, 2011 52
Table 36: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Overall Sponsors, 2011 53
Table 37: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Prominent Sponsors, 2011 54
Table 38: Leiomyosarcoma Therapeutics, Top Companies Participating in Clinical Trials, 2011 55
Table 39: Ariad Pharmaceuticals, Leiomyosarcoma Pipeline Product, 2011 58
Table 40: Merck & Co., Leiomyosarcoma Pipeline Product, 2011 60
Table 41: Threshold Pharmaceuticals Inc., Leiomyosarcoma Pipeline Product, 2011 62
Table 42: GlaxoSmithKline, Leiomyosarcoma Pipeline Product, 2011 63
Table 43: Eisai Co., Ltd., Leiomyosarcoma Pipeline Product, 2011 65

List of Figures
1.2 List of Figures
Figure 1: Leiomyosarcomas at Different Locations in the Body 8
Figure 2: Treatment Algorithm for Leiomyosarcoma 13
Figure 3: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 15
Figure 4: Leiomyosarcoma Therapeutics Major Market Share , 2011 16
Figure 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019 17
Figure 6: Leiomyosarcoma Therapeutics Major Market Share ($m), 2019 18
Figure 7: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011 19
Figure 8: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019 20
Figure 9: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011 21
Figure 10: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 22
Figure 11: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 23
Figure 12: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019 24
Figure 13: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 25
Figure 14: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 26
Figure 15: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 27
Figure 16: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 28
Figure 17: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 29
Figure 18: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 30
Figure 19: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
Figure 20: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 32
Figure 21: Drivers and Barriers for Leiomyosarcoma Therapeutics, 2011 34
Figure 22: Opportunity and Unmet Need in the Leiomyosarcoma Therapeutics Market, 2011 34
Figure 23: Leiomyosarcoma Therapeutics, Strategic Competitor Assessment, 2011 37
Figure 24: Leiomyosarcoma Therapeutics - Pipeline by Phase of Development, 2011 38
Figure 25: Leiomyosarcoma Therapeutics, Pipeline by Mechanism of Action (%), 2011 41
Figure 26: Technology Trends Analytical Framework of the Leiomyosarcoma Pipeline, 2011 42
Figure 27: Technology Trends Analytical Framework of Leiomyosarcoma Pipeline - Description, 2011 43
Figure 28: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011 50
Figure 29: Leiomyosarcoma Therapeutics, Clinical Trials by Phase (%), 2011 51
Figure 30: Leiomyosarcoma Therapeutics, Clinical Trials by Status (%), 2011 52
Figure 31: Leiomyosarcoma Therapeutics, Clinical Trials by Overall Sponsors (%), 2011 53
Figure 32: Leiomyosarcoma Therapeutics, Clinical Trials by Prominent Sponsors (%), 2011 54
Figure 33: Leiomyosarcoma Therapeutics, Companies Participating in Therapeutic Clinical Trials, 2011 55
Figure 34: Implications for Future Market Competition in Leiomyosarcoma Therapeutic Market, 2011 56
Figure 35: Leiomyosarcoma Therapeutics, Number of Pipeline Molecules by Company, 2011 57
Figure 36: GlobalData Market Forecasting Model 71

Title Date Price
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00
2010 U.S. Medical & Surgical Hospitals Industry Report
By Barnes Reports
The Medical & Surgical Hospitals Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current a ...Read More
Oct 2009 $149.00
2010 U.S. Medical Laboratories Industry Report
By Barnes Reports
The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More
Oct 2009 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z